# An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Source: https://onco.cc/trials/nct06401356/  
OnCo record `nct06401356` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Pelabresib, now recruiting.

## Summary

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib is a phase 3 interventional study registered as NCT06401356, led by Novartis Pharmaceuticals, and recruiting on the registry. Official title: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib. Planned enrolment is 50 participants (estimated). The study started in 2024-08-13 and primary completion is expected in 2027-06-02. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06401356
- Phase: 3
- Setting: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06401356: https://clinicaltrials.gov/study/NCT06401356

## Connected records

- drugs: [Pelabresib](https://onco.cc/drugs/pelabresib/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct06401356.json